1. Epigenetic regulation of hepatic Dpp4 expression in response to dietary protein
   Sophie Saussenthaler et al, 2019, The Journal of Nutritional Biochemistry CrossRef
2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block
   Vasilios G. Athyros et al, 2020, Current Vascular Pharmacology CrossRef
3. Liver and insulin resistance: New wine in old bottle!!!
   Bhoomika M. Patel et al, 2019, European Journal of Pharmacology CrossRef
4. Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis
   Bingli Liu et al, 2023, Cell Death & Disease CrossRef
5. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
   Mitsuhiro Kawakubo et al, 2020, Scientific Reports CrossRef
6. Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
   Jin Hyun Kim et al, 2020, International Journal of Molecular Sciences CrossRef
7. Feprazone Displays Antiadipogenesis and Antiobesity Capacities in in Vitro 3 T3-L1 Cells and in Vivo Mice
   Liqun Che et al, 2021, ACS Omega CrossRef
8. The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats
   Ahmed Mohamed Othman et al, 2023, Biomedicines CrossRef
9. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
   Minyoung Lee et al, 2020, Scientific Reports CrossRef
10. Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model
    Takumi Kawaguchi et al, 2019, Liver Cancer CrossRef
11. DPP-4 inhibition resembles exercise in preventing type 2 diabetes development by inhibiting hepatic protein kinase Cε expression in a mouse model of hyperinsulinemia
    Yu-peng Li et al, 2020, Journal of International Medical Research CrossRef
12. Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
    Ju Hee Oh et al, 2022, Clinical and Molecular Hepatology CrossRef
13. Role of X-Box Binding Protein-1 in Fructose-Induced De Novo Lipogenesis in HepG2 Cells
    Xian Yu et al, 2018, Chinese Medical Journal CrossRef
14. Bovine α-lactalbumin hydrolysates (α-LAH) attenuate high-fat diet induced nonalcoholic fatty liver disease by modulating hepatic lipid metabolism in C57BL/6J mice
    Jing Gao et al, 2019, Journal of Functional Foods CrossRef
15. Dipeptidyl Peptidase-IV Inhibitory Activity and Related Molecular Mechanism of Bovine α-Lactalbumin-Derived Peptides
    Jing Gao et al, 2020, Molecules CrossRef
16. A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
    Seonghwan Hwang et al, 2022, Clinical and Molecular Hepatology CrossRef
17. Ethanol Extract of Pinus koraiensis Leaves Mitigates High Fructose-Induced Hepatic Triglyceride Accumulation and Hypertriglyceridemia
    Min-Ho Lee et al, 2022, Applied Sciences CrossRef
18. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
    Amalia Gastaldelli et al, 2019, JHEP Reports CrossRef